Abstract
Objectives: Sulfonylurea derivatives are widely used for clinical treatment of human subjects with Maturity Onset Diabetes of the Young (MODY) caused by mutations in HNF-1 or HNF-4 despite the mechanism leading to their hypersensitivity is incompletely understood. In Hnf1a-/- mice, serum concentrations and half-life of sulfonylurea derivatives are strongly increased. We thus hypothesized that reduced sulfonylurea derivatives clearance stands behind their therapeutic potential in human HNF1A/HNF4A MODY subjects.
Design and Methods: Single doses of 3 mg glipizide and 5 mg glibenclamide/glyburide were administered sequentially to seven HNF1A/HNF4A MODY subjects and six control individuals matched for their age, BMI and CYP2C9 genotype. Pharmacokinetic (plasma concentration levels, Cmax, tmax, t1/2, AUC) and pharmacodynamic parameters (glycemia, C-peptide and insulin plasma levels) were followed for 24 hours after drug administration.
Results: We provide the first evidence on the pharmacokinetics and pharmacodynamics of sulfonylurea derivatives in human MODY subjects. The half-life of glipizide did not change, and reached 3.8±0.7 and 3.7±1.8 h in the MODY and control subjects, respectively. The half-life of glibenclamide was increased only in some MODY subjects (t1/2 9.5±6.7 and 5.0±1.4 h, respectively). Importantly, the intra- individual responses of MODY (but control) subjects to glipizide and glibenclamide treatment were highly correlated. With regards to pharmacodynamics, we observed a differential response of control but not MODY subjects to the doses of glipizide and glibenclamide applied.
Conclusions: We rejected the hypothesis that all human MODY-associated mutations in HNF1A / HNF4A induce changes in the pharmacokinetics of sulfonylureas in humans analogically to the Hnf1a-/- mouse model.
Keywords: Diabeta, glibenclamide, glipizide, glucotrol, glyburide, glynase, liver oxidation of xenobiotics, micronase, MODY diabetes, second generation sulfonylurea.
Current Pharmaceutical Design
Title:Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a-/- Model
Volume: 21 Issue: 39
Author(s): Jana Urbanova, Michal Andel, Jana Potockova, Josef Klima, Jan Macek, Pavel Ptacek, Vaclav Mat’oska, Tereza Kumstyrova and Petr Heneberg
Affiliation:
Keywords: Diabeta, glibenclamide, glipizide, glucotrol, glyburide, glynase, liver oxidation of xenobiotics, micronase, MODY diabetes, second generation sulfonylurea.
Abstract: Objectives: Sulfonylurea derivatives are widely used for clinical treatment of human subjects with Maturity Onset Diabetes of the Young (MODY) caused by mutations in HNF-1 or HNF-4 despite the mechanism leading to their hypersensitivity is incompletely understood. In Hnf1a-/- mice, serum concentrations and half-life of sulfonylurea derivatives are strongly increased. We thus hypothesized that reduced sulfonylurea derivatives clearance stands behind their therapeutic potential in human HNF1A/HNF4A MODY subjects.
Design and Methods: Single doses of 3 mg glipizide and 5 mg glibenclamide/glyburide were administered sequentially to seven HNF1A/HNF4A MODY subjects and six control individuals matched for their age, BMI and CYP2C9 genotype. Pharmacokinetic (plasma concentration levels, Cmax, tmax, t1/2, AUC) and pharmacodynamic parameters (glycemia, C-peptide and insulin plasma levels) were followed for 24 hours after drug administration.
Results: We provide the first evidence on the pharmacokinetics and pharmacodynamics of sulfonylurea derivatives in human MODY subjects. The half-life of glipizide did not change, and reached 3.8±0.7 and 3.7±1.8 h in the MODY and control subjects, respectively. The half-life of glibenclamide was increased only in some MODY subjects (t1/2 9.5±6.7 and 5.0±1.4 h, respectively). Importantly, the intra- individual responses of MODY (but control) subjects to glipizide and glibenclamide treatment were highly correlated. With regards to pharmacodynamics, we observed a differential response of control but not MODY subjects to the doses of glipizide and glibenclamide applied.
Conclusions: We rejected the hypothesis that all human MODY-associated mutations in HNF1A / HNF4A induce changes in the pharmacokinetics of sulfonylureas in humans analogically to the Hnf1a-/- mouse model.
Export Options
About this article
Cite this article as:
Urbanova Jana, Andel Michal, Potockova Jana, Klima Josef, Macek Jan, Ptacek Pavel, Mat’oska Vaclav , Kumstyrova Tereza and Heneberg Petr, Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a-/- Model, Current Pharmaceutical Design 2015; 21 (39) . https://dx.doi.org/10.2174/1381612821666151008124036
DOI https://dx.doi.org/10.2174/1381612821666151008124036 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases
Current Drug Safety The Biochemical Parameters and Vitamin D Levels in ICU Patients with Covid-19: A Cross-Sectional Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Regulation of Na+/K+-ATPase by Estradiol and IGF-1 in Cardio-Metabolic Diseases
Current Pharmaceutical Design Human Cognitive and Neuro-Psychiatric Bio-Markers in the Cardiac Peri-Operative Patient
Current Molecular Medicine The Heme Oxygenase System and Type-1 Diabetes
Current Pharmaceutical Design Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Fluoxetine and all other SSRIs are 5-HT<sub>2B</sub> Agonists - Importance for their Therapeutic Effects
Current Neuropharmacology Visceral and Subcutaneous Adiposity: Are Both Potential Therapeutic Targets for Tackling the Metabolic Syndrome?
Current Pharmaceutical Design How Would Composite Traditional Chinese Medicine Protect the Brain – An Example of the Composite Formula “Pien Tze Huang”
Current Medicinal Chemistry Benzodiazepines, Amphetamines, Testosterone, and Sildenafil as New Candidate Drugs for Sexual Interest, Desire and/or Arousal Disorder
Current Psychopharmacology A Systematic Approach to Hypertensive Urgencies and Emergencies
Current Hypertension Reviews Chaperonopathies and Chaperonotherapy. Hsp60 as Therapeutic Target in Cancer: Potential Benefits and Risks
Current Pharmaceutical Design Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer's Disease
Current Alzheimer Research Epigenetic Modulation of Myocardial Angiogenic Balance: An Emerging Therapeutic Perspective for Adult Failing Heart
Current Angiogenesis (Discontinued) Evaluation of Plasma Homocysteine Levels as a Prognostic Factor for the Occurrence of Perioperative Myocardial Infarction in Coronary Artery Bypass Grafting: A Pilot Study
Vascular Disease Prevention (Discontinued) Eplerenone, a New Selective Aldosterone Blocker
Current Pharmaceutical Design Chromogranin-A: A Multifaceted Cardiovascular Role in Health and Disease
Current Medicinal Chemistry Opioid Growth Factor and its Derivatives as Potential Non-toxic Multifunctional Anticancer and Analgesic Compounds
Current Medicinal Chemistry Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update
Current Cardiology Reviews Peripheral Arterial Disease and Oxidative Stress
Vascular Disease Prevention (Discontinued)